Congestive heart failure and expression of myocardial urotensin II

Human urotensin II has several cardiovascular actions, including potent vasoactive, and cardiac inotropic and hypertropic properties. Our aim was to ascertain degree of expression of urotensin II and its receptor GPR14 (now known as UT receptor) in the myocardium of patients with congestive heart fa...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2002-06, Vol.359 (9322), p.1990-1997
Main Authors: Douglas, Stephen A, Tayara, Lara, Ohlstein, Eliot H, Halawa, Nadine, Giaid, Adel
Format: Article
Language:English
Subjects:
Adult
Analysis of Variance
Biological and medical sciences
Cardiology. Vascular system
Cardiomyopathy, Dilated - metabolism
Cardiomyopathy, Dilated - pathology
Cardiovascular diseases
Clinical trials
Female
Fluorescein-5-isothiocyanate
Fluorescent Dyes
Heart
Heart failure
Heart Failure - metabolism
Heart Failure - pathology
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Hemodynamics
Humans
In Situ Hybridization
Male
Medical sciences
Middle Aged
Myocardium - pathology
Receptors, Cell Surface - metabolism
Receptors, G-Protein-Coupled
Reverse Transcriptase Polymerase Chain Reaction
Urotensins - isolation & purification
Urotensins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human urotensin II has several cardiovascular actions, including potent vasoactive, and cardiac inotropic and hypertropic properties. Our aim was to ascertain degree of expression of urotensin II and its receptor GPR14 (now known as UT receptor) in the myocardium of patients with congestive heart failure (CHF). We obtained specimens of myocardium from the hearts of 19 patients with end-stage CHF (12 ischaemic heart disease, seven dilated cardiomyopathy), five patients with early-stage CHF, and eight healthy controls. We used immunohistochemistry, in-situ hybridisation, reverse transcriptase-PCR (RT-PCR), and fluorescein isothiocyanate (FITC)-conjugated urotensin II to ascertain degree of myocardial expression of urotensin II and binding urotensin receptor. Our results showed strong expression of urotensin II in the cardiomyocytes, and to a lesser extent in the vascular smooth muscle cells, endothelial cells, and inflammatory cells of patients with end-stage CHF. There was significantly less urotensin II expression in the myocardium of patients with early-stage CHF (p
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(02)08831-1